Critically ill patients: lung microbiome may help predict outcomes
Changes in the lung microbiome may help predict how well critically ill patients will respond to care.
Specifically, patients with higher levels of lung bacteria one day after admission to the ICU Intensive Care Unit ) had fewer ventilator-free days, a strong effect that was not explained by severity of critical illness or the presence of pneumonia.
The identity of lung microbiota was also predictive of ICU outcomes in these patients. Two bacteria normally found in the gut ( Lachnospiraceae and Enterobacteriaceae spp ) were common in the lung microbiome of patients who had worse ICU outcomes.
The presence of Enterobacteriaceae spp in the lung microbiome was also associated with acute respiratory distress syndrome, or ARDS, a life-threatening illness in which the lungs are severely inflamed.
Prior studies found that the immune function of patients with ARDS is highly variable and that the translocation of gut bacteria to the lungs may play a role in the development of ARDS.
In another earlier study, the researchers showed that the lung microbiome in patients with idiopathic pulmonary fibrosis, or IPF, is also predictive of clinical outcomes.
The human microbiome comprises the genetic material of an estimated 100 trillion microbes. Bacteria is the biggest component of the microbiome, but it also includes viruses, fungi and archaea.
Unlike the human genome, which is relatively static, the microbiome is altered, sometimes dramatically, by diet, disease and other factors.
While the lungs have historically been considered sterile, in the past decade investigators have used DNA-based methods to reveal that the lung contain diverse and dynamic communities of bacteria.
In their study of 91 critically ill patients, the researchers controlled for disease severity and for whether the patient had pneumonia, which would increase the number of bacteria in the lung microbiome.
After taking these factors into account, the associations between ventilator-free days and the bacteria level and detection of gut-associated bacteria in the lung microbiome persisted.
The lung microbiome may represent a novel target for preventing and treating critical illness.
Study limitations include the fact that researchers could not control for medications, including antibiotics, that the patients may have taken before being admitted to the ICU.
The researchers could not determine if the gut-associated bacteria found in some patients' lung microbiome had migrated from the lower gastrointestinal tract or whether they were found in the lungs because of aspiration, the accidental inhalation of food or liquid. ( Xagena )
Source: Journal of Respiratory and Critical Care Medicine, 2020
Real-world ACS population: Ticagrelor doesn’t lessen risks of myocardial infarction or death and may increase bleeding relative to Clopidogrel
Major bleeding after acute coronary syndrome predicts a poor outcome but is challenging to define. The choice of antiplatelet influences...
Diabetic patients with COVID-19, characteristics and outcome: a two-centre, retrospective, case control study
Since December 2019, a pneumonia caused by SARS-CoV-2 which was later named as COVID-19 emerged and many people lost...
Coronavirus disease 2019 ( COVID-19 ) is a pandemic with no specific therapeutic agents and substantial mortality. It is...
SARS-CoV-2 uses the angiotensin-converting enzyme ( ACE ) 2 receptor for entry into target cells. ACE2 is predominantly expressed by...
Initial preliminary findings from the Papa Giovanni XXIII Hospital sponsored SISCO ( Siltuximab In Serious COVID-19 ) Study, based on...
ESC 2019 - ENTRUST-AF PCI trial: Edoxaban dual therapy noninferior to triple therapy in atrial fibrillation post-stenting
Edoxaban ( Lixiana ) in combination with a P2Y12 inhibitor is noninferior to standard triple therapy for preventing bleeding in...
FDA has approved treatment for patients with endometrial carcinoma: Lenvima in combination with Keytruda
The FDA ( U.S. Food and Drug Administration ) has announced Project Orbis, an initiative of the FDA Oncology Center...
A study has evaluated the efficacy and tolerability of intravenous Lacosamide ( LCM-iv ) under routine conditions in daily clinical...
Kawasaki disease: high-dose Aspirin is associated with anemia and does not confer benefit to disease outcomes
Kawasaki disease ( KD ) is also known as multiple mucocutaneous lymph node syndrome of systemic vasculitis and is a...